Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03597139 · ClinicalTrials.gov registry record · Phase 2
Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease
A Phase 2 study, sponsored by Aurinia Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT03597139 is a Phase 2 study that has completed, run by Aurinia Pharmaceuticals. The registered enrollment target is 100 participants.
The verdict
NCT03597139, a Phase 2 study, has completed, sponsored by Aurinia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
Evaluate the tolerability, efficacy and safety of VOS versus Restasis® in subjects with mild to moderate Dry Eye Disease (DED).
Interventions
- DRUG Voclosporin Ophthalmic Solution
- DRUG Restasis®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-08-13 |
| Est. Completion | 2018-12-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03597139
The ClinicalTrials.gov registry entry for NCT03597139 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aurinia Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Voclosporin Ophthalmic Solution is the first listed.
NCT03597139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03597139 about?
NCT03597139 is a clinical study titled "Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease". Evaluate the tolerability, efficacy and safety of VOS versus Restasis® in subjects with mild to moderate Dry Eye Disease (DED).
What is the current status of trial NCT03597139?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2018-08-13. Estimated completion is 2018-12-13.
What interventions are being tested in trial NCT03597139?
The interventions under investigation include: Voclosporin Ophthalmic Solution (DRUG), Restasis® (DRUG).
Who is sponsoring clinical trial NCT03597139?
This trial is sponsored by Aurinia Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.